| Biomarker ID | 546 |
| PMID | 20957673 |
| Year | 2011 |
| Biomarker | Sarcosine |
| Biomarker Basis | Expression Based |
| Biomolecule | Metabolites |
| Source | Urine |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: OR: 1.040 (95% CI: 1.009 – 1.072); Multivariate: OR: 1.046 (95% CI: 1.009-1.084) |
| Effect on Pathways | Pathways Include: Glycine, serine and threonine metabolism,Metabolism |
| Experiment | Cancer Vs No Malignancy (PSA Range: 4-10) |
| Type of Biomarker | Diagnostic |
| Cohort | 86 untreated patients with CaP and 45 patients with no evidence of malignancy |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.659 (95% CI: 0.555-0.764) |
| Accuracy | NA |
| Level Of Significance | Univariate: p=0.011; Multivariate: p=0.015 |
| Method Used | Liquid Chromatography-Mass Spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SARDH |